Curosurf (Poractant Alfa)

Curosurf (Poractant Alfa) is a surfactant replacement therapy used to treat respiratory distress syndrome in premature infants. This product helps improve lung function and oxygenation, supporting critical care for newborns.

Curosurf is primarily used to treat respiratory distress syndrome (RDS) in premature infants. This condition occurs when the lungs are not fully developed and lack sufficient surfactant, a substance that keeps the air sacs open. Curosurf replenishes this surfactant, aiding in better lung expansion and reducing the work of breathing. It is administered via endotracheal tube directly into the lungs.

Curosurf works by coating the inner surface of the lungs, reducing surface tension and preventing the collapse of alveoli. This action helps improve oxygenation and lung compliance, making it easier for premature infants to breathe. The effects are typically observed shortly after administration.

Curosurf should be administered by trained healthcare professionals in a controlled medical setting. It is crucial to follow proper handling and storage guidelines to maintain its efficacy. As with any medical intervention, monitoring for any adverse reactions is essential.

Curosurf is generally used in a controlled medical environment where interactions with other medications are carefully managed. However, it is important to inform healthcare providers about any other treatments the infant is receiving to avoid potential complications.